Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

11/17/2026 | Press release | Distributed by Public on 11/16/2026 18:53

AR1001 Achieved Primary Efficacy Objective in Phase 3 POLARIS-AD Trial in Alzheimer’s Disease, Slowing Clinical Decline in Prespecified Monotherapy Population

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 00:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]